Vilnius

As one of the fastest-growing life sciences hubs in Europe, Vilnius is a premier destination for biotechnology innovation and pharmaceutical manufacturing.

The city is globally recognized for its pioneering leadership in gene editing, driven by the world-class Vilnius University Life Sciences Center and its strategic partnership with the EMBL for CRISPR-Cas9 research.

Beyond genomics, Vilnius boasts a robust biopharmaceutical sector, featuring major players like Thermo Fisher Scientific and specialized CDMOs such as Northway Biotech, which provide end-to-end drug development services.

The ecosystem is rapidly expanding into medical device technology and digital health, supported by the cutting-edge Santara Science Valley and the ambitious Bio City, set to be the largest biotech complex in Europe.

Investors and startups benefit from a business-friendly environment focused on precision medicine, synthetic biology and clinical research excellence.

With a highly skilled talent pool where over 60% of scientists are women, the city excels in recombinant protein production and molecular biology R&D.

Furthermore, the Vilnius City Innovation Industrial Park offers state-of-the-art labs and GMP-certified facilities for companies scaling from pilot to commercial production.

By integrating AI-driven drug discovery with traditional healthcare innovation, Vilnius is solidifying its role as a vital node in the global life sciences supply chain.

This collaborative environment, highlighted annually at the Life Sciences Baltics forum, ensures that scientific breakthroughs are efficiently translated into market-ready therapeutic solutions.